A three‐microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults, characterized by aggressive growth, limited response to therapy, and inexorable recurrence. Because of the extremely unfavorable prognosis of GBM, it is important to develop more effective diagnostic and therapeutic strategies based on biologically and clinically relevant patient stratification systems. Analyzing a collection of patient‐derived GBM stem‐like cells (GSCs) by gene expression profiling, nuclear magnetic resonance spectroscopy, and signal transduction pathway activation, we identified two GSC clusters characterized by different clinical features. Due to the widely documented role played by microRNAs (miRNAs) in the tumorigenesis process, in this study we explored whether these two GBM patient subtypes could also be discriminated by different miRNA signatures. Global miRNA expression pattern was analyzed by oblique principal component analysis and principal component analysis. By a combined inferential strategy on PCA results, we identified a reduced set of three miRNAs – miR‐23a, miR‐27a, and miR‐9* (miR‐9‐3p) – able to discriminate the proneural‐ and mesenchymal‐like GSC phenotypes as well as mesenchymal and proneural subtypes of primary GBM included in The Cancer Genome Atlas (TCGA) data set. Kaplan–Meier analysis showed a significant correlation between the selected miRNAs and overall survival in 429 GBM specimens from TCGA‐identifying patients who had an unfavorable outcome. The survival prognostic capability of the three‐miRNA signatures could have important implications for the understanding of the biology of GBM subtypes and could be useful in patient stratification to facilitate interpretation of results from clinical trials.

[1]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Stephen Safe,et al.  The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. , 2007, Cancer research.

[3]  F. Berger,et al.  MicroRNAs: molecular features and role in cancer. , 2012, Frontiers in bioscience.

[4]  K. Camphausen,et al.  Visualizing Molecular Profiles of Glioblastoma with GBM-BioDP , 2014, PloS one.

[5]  Xia Li,et al.  Dissecting dysfunctional crosstalk pathways regulated by miRNAs during glioma progression , 2016, Oncotarget.

[6]  Tae-Min Kim,et al.  A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. , 2011, Cancer research.

[7]  Dan Chen,et al.  Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10 , 2013, Scientific Reports.

[8]  S. Volinia,et al.  A MiRNA Signature for Defining Aggressive Phenotype and Prognosis in Gliomas , 2014, PloS one.

[9]  H. H. Andersen,et al.  MicroRNA Expression Signatures Determine Prognosis and Survival in Glioblastoma Multiforme—a Systematic Overview , 2014, Molecular Neurobiology.

[10]  Songshan Jiang,et al.  miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1. , 2013, International journal of oncology.

[11]  L. Ricci-Vitiani,et al.  Expression of EGFRvIII in glioblastoma: prognostic significance revisited. , 2011, Neoplasia.

[12]  A. Baruzzi,et al.  Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III , 2014, Molecular oncology.

[13]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[14]  M. Westphal,et al.  A distinct subset of glioma cell lines with stem cell‐like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target , 2011, Glia.

[15]  G. Crabtree,et al.  MicroRNA-mediated switching of chromatin-remodelling complexes in neural development , 2009, Nature.

[16]  Yuri Kotliarov,et al.  Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. , 2009, Cancer research.

[17]  P. Pu,et al.  A predicted miR-27a-mediated network identifies a signature of glioma. , 2012, Oncology reports.

[18]  Chang Liu,et al.  An Exploration of Evolution, Maturation, Expression and Function Relationships in Mir-23∼27∼24 Cluster , 2014, PloS one.

[19]  M. Nikiforova,et al.  Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.

[20]  L. Ricci-Vitiani,et al.  miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal , 2015, Oncotarget.

[21]  Helen Wheeler,et al.  miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. , 2011, European journal of cancer.

[22]  L. Ricci-Vitiani,et al.  Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[23]  K. Somasundaram,et al.  Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma , 2010, Modern Pathology.

[24]  B. Purow,et al.  Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs. , 2014, Neuro-oncology.

[25]  Xiaozhong Peng,et al.  cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a , 2012, Proceedings of the National Academy of Sciences.

[26]  Yan Jiang,et al.  MiR-27a-3p promotes esophageal cancer cell proliferation via F-box and WD repeat domain-containing 7 (FBXW7) suppression. , 2015, International journal of clinical and experimental medicine.

[27]  R. Preisendorfer,et al.  Principal Component Analysis in Meteorology and Oceanography , 1988 .

[28]  Curtis D. Mobley,et al.  The Principal Discriminant Method of Prediction: Theory and Evaluation , 1988 .

[29]  J. Kuo,et al.  MicroRNAs in cancer: Glioblastoma and glioblastoma cancer stem cells , 2014, Neurochemistry International.

[30]  N. Potter,et al.  Genetic and Functional Diversity of Propagating Cells in Glioblastoma , 2014, Stem cell reports.

[31]  S. Fu,et al.  MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2 in laryngeal carcinoma , 2014, BMC Cancer.

[32]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[33]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[34]  A. Palma,et al.  Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome , 2016, Scientific Reports.

[35]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[36]  A. Stegh,et al.  miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics , 2015, Cell cycle.

[37]  Yun-jie Wang,et al.  Identification of low miR-105 expression as a novel poor prognostic predictor for human glioma. , 2015, International journal of clinical and experimental medicine.

[38]  R. Pallini,et al.  Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme , 2008, International journal of cancer.

[39]  L. Ricci-Vitiani,et al.  Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis , 2013, Cancer.

[40]  Daniele C. Struppa,et al.  Agnostic Science. Towards a Philosophy of Data Analysis , 2011 .

[41]  Yun-jie Wang,et al.  Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma. , 2015, International journal of clinical and experimental pathology.

[42]  M. Weller,et al.  CAMTA1 is a novel tumour suppressor regulated by miR‐9/9* in glioblastoma stem cells , 2011, The EMBO journal.

[43]  Ming Li,et al.  Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. , 2014, Cancer research.

[44]  Lynda Chin,et al.  Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.

[45]  Min Liu,et al.  MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. , 2009, Cancer letters.

[46]  R. Shi,et al.  Anti-miRNA-23a oligonucleotide suppresses glioma cells growth by targeting apoptotic protease activating factor-1. , 2013, Current pharmaceutical design.

[47]  K. Tsujikawa,et al.  Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma. , 2015, Oncotarget.

[48]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[49]  N. Saini,et al.  Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases , 2010, Molecular Cancer.

[50]  K. Aldape,et al.  A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.

[51]  M. Mizoguchi,et al.  Clinical implications of microRNAs in human glioblastoma , 2013, Front. Oncol..

[52]  S. Prakash Sethi,et al.  Comparative Cluster Analysis for World Markets , 1971 .

[53]  Michael Sabel,et al.  Genomic and Expression Profiling of Glioblastoma Stem Cell–Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival , 2009, Clinical Cancer Research.

[54]  Alessandro Giuliani,et al.  Hematopoietic differentiation: a coordinated dynamical process towards attractor stable states , 2010, BMC Systems Biology.

[55]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[56]  P. Jolicoeur,et al.  Size and shape variation in the painted turtle. A principal component analysis. , 1960, Growth.

[57]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[58]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[59]  J. Michálek,et al.  MiR‐195, miR‐196b, miR‐181c, miR‐21 expression levels and O‐6‐methylguanine‐DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients , 2011, Cancer science.

[60]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.